FDA approves new kind of treatment for hairy cell leukemia

• 来源期刊: 中国药学（英文版）
• 年，卷（期）: 2018,（9）
• 页码范围: 649
• 页数: 1页
• 语种: 英文

摘要

The U.S.Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies,including treatment with a purine nucleoside analog.Lumoxiti is a CD22-directed cytotoxin and is the first of this type of treatment for patients with HCL.